Navigation LinksBiology NewsHealth NewsBiology TechnologyMedicine Technology


Is Your Company Risk Appropriate?

The Big Question I have often said: The problem is that too many companies are out seeking risk capital that isn't appropriate for them. How can I support this statement? After all, entrepreneurship is the primary driver of growth and job creation in the US. From 1979 to 1995, the Fortune 500 shed 4 million jobs, while entrepreneurial firms created 24 million jobs. I'm not sugg...

Board Pieces

Creating a board for a start-up tech company may seem low on the priority scheme. Alternately, it may appear easy just sign up the most qualified people available. Neither is true. The board of directors for an early stage company should support and mentor senior management. Eventually the board should become a entity that promotes, supports, and guides the long-term strategic plan for the b...

Boundaryless: Economic Development?

Jack Welch used the word boundaryless to describe his vision for GE. Specifically, Welch wanted to do away with the hierarchical, get-seven-signatures-before-buying-toilet-paper, bureaucratic B.S. that crippled GEs ability to move nimbly into markets, execute quickly on decisions, and empower people. Economic developers would do well to tear a note from Welchs playbook. Why? Because markets ar...

Quintessence Secures Financing

MADISON, WI. - Quintessence Biosciences, Inc., a biotechnology company developing pharmaceutical products for use in research, has finalized a three million dollar financing deal. The majority of the funding, $2.3 million, was received from individual investors, and the remainder was borrowed from the Madison Development Corporation, Wisconsin Department of Commerce, and m2 Lease Funds, a private...

The Making of Chicago as a Biotech Cluster

On May 15, I had the opportunity to attend an exciting Chicago networking event that was organized by Women Advancing Biosciences . The event featured a presentation by professor Alicia Loffler, who is the director of the Kellog Center for Biotechnology at Northwestern University . Lofflers presentation addressed the key biotech clusters in the U.S. and the core ingredients needed to make...

Wisconsins Real-Time" Economy

MADISON, WI - Wisconsins economy needs new thoughts, new processes, and new innovations, but the term The New Economy no longer works. The New Economy is an old worn-out phase used in Silicon Valley in the late 1990s is now associated with greed, lies, lavish spending and corruption as well as cute, but not profitable or sustainable business models. The future Wisconsin Economy will unfold in...

Are We Headed for a Global Economic Collapse?

The first three days of June, the first through the third, will be most interesting to watch because thats when the G-8, US, Japan, Germany, France, Italy, Britain, Canada and Russia, have their annual meeting to discuss global issues. Unfortunately, China is missing from the party, and given their importance on the global stage, thats a huge mistake! Usually these meetings are photo opportun...

Lowering the fear factor for entrepreneurs, intra-preneurs

MILWAUKEE,WI.-Beware calling the next strange idea you hear strange: the person touting it just might be the next millionaire next door. A panel of experienced entrepreneurs speaking to attendees at the first Wisconsin Entrepreneurs Conference in Milwaukee last Wednesday have dealt with looks and whispers their entire working lives, and they encouraged their brethren in the audience to accept...

Employer Brands Require More Than Slick Marketing

Successful internal brand building requires more than a marketing campaign and the involvement of the marketing department. Key people in the organization (HR managers, senior executives and middle managers responsible for creating the product - in this case, the employee experience) play a vital role in marketing the brand. Employees today are too savvy for marketing-style campaigns alone to wor...

The ON* is on the Employer

By 2008, our economy will have a different look and feel as traditionalists (b. 1925 1942) and baby boomers (b. 1943 1960) continue to exit the workforce, by choice or not. Employers will be facing an HR supply-demand nightmare - an excess of 10 million unfilled jobs combined with a shortage of young talent to fill these positions. That does not leave much time to educate, attract, grow and re...
[next]
(Date:11/3/2009)..., FL (November 4, 2009) For more than 25 years, a...ch ( Strombus gigas ) have been unsuccessfuluntil ...ding techniques to produce beaded (nucleated) and ...ve been developed by scientists from Florida Atlan...tute (HBOI). With less than two years of research ...
(Date:11/3/2009)..., FLLaser labeling of fruit and vegetables is a ne...n dioxide laser beam is used to label, or "etch" i...d for common sticker-type labels. The technology h...d vegetables and is being used in New Zealand, Aus...n approved in Asia, South Africa, Central and Sout...
(Date:11/3/2009)...m the UCLA Henry Samueli School of Engineering and...lly reconstituted in the laboratory the enzyme res...-lowering drug lovastatin. , The research, pu...tentially lead to the development of other compoun...ovastatin-synthesizing enzyme is one of the most i...
Breaking Biology News(10 mins):Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 2Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 3Laser etching safe alternative for labeling grapefruit 2UCLA researchers reconstitute enzyme that synthesizes cholesterol drug lovastatin 2CureDM Awarded 2009 Diabetes Product Innovation of the Year by Frost and Sullivan 56630 1CureDM Awarded 2009 Diabetes Product Innovation of the Year by Frost and Sullivan 56630 2CureDM Awarded 2009 Diabetes Product Innovation of the Year by Frost and Sullivan 56630 3Vitro 26apos 3Bs Cancer Stem Cell Therapy Complements New Hedge Hog Drugs 56629 1Vitro 26apos 3Bs Cancer Stem Cell Therapy Complements New Hedge Hog Drugs 56629 2Vitro 26apos 3Bs Cancer Stem Cell Therapy Complements New Hedge Hog Drugs 56629 3Vitro 26apos 3Bs Cancer Stem Cell Therapy Complements New Hedge Hog Drugs 56629 4HMS Holdings Corp to Present at Investor Conferences 56627 1
...niversities have come together to form the Global ...ce brings together these leading engineering-based...ays to address global societal issues is through t...l solutions based on top class research in science...by the Alliance include biomedicine and health car...
...ersity have found that a tiny aquatic plant can be...arms and potentially be part of the answer for the...rowing duckweed on hog wastewater can produce five...rding to researcher Dr. Jay Cheng. This means that...r and cheaper than from corn," says fellow researc...
...UC) and its affiliated health care partners will r...utes of Health (NIH) to bring innovations from the...ns within the community. , The five-year funding,...and Translational Science Awards (CTSA) program, w...ter for Clinical and Translational Science and Tra...
Other Biology News:Global alliance of leading technological universities to address global societal issues 2Tiny super-plant can clean up animal waste and be used for ethanol production 2UC and partners awarded $23 million to transform discoveries into real-world health solutions 2UC and partners awarded $23 million to transform discoveries into real-world health solutions 3
LIC Duet™ Trx•Tag™ Ek Adaptor from Novagen
Corning Culture Flask, 25 cm2, Tc-Treated, Angled Neck, Phenolic-Style Cap, Sterile from Sigma-Aldrich
Newborn Calf serum from Equitech-Bio
Corning Culture Flask, 75 cm2, Tc-Treated, Angled Neck, Plug Seal, Sterile from Sigma-Aldrich
Biology Products:
(Date:11/5/2009)..., Nov. 5 GenVec, Inc. (N...ts for the third quarter ended September 30, 2009.... per share) for the three months ended September 3....08 per share) in the comparable quarter of 2008. ...ec,s net loss was $14.1 million ($0.15 per share),...
(Date:11/5/2009)... Nov. 5 DSM Pharmaceutical Product... alliance with Galenix, Saint Jean D,Illac, France... manufacturing partner for Galenix commercial prod... collaborate on business development opportunities...based on the strength of Galenix in drug product d...
(Date:11/5/2009)...alif., Nov. 5 ThermoGene...innovative products for processing and storing adu...t quarter of fiscal 2010. ,, For the quarter en...ues of $5.2 million, a 15 percent increase over re... ago. The Company said the key contributors to the...
(Date:11/5/2009)... 5 Transgenomic, Inc. (O... results for the quarter ended September 30, 2009....the tables that follow. ,, Third Quarter 2009 ... or $0.01 per share for the third quarter of 2009 ... share for the third quarter of 2008. ,, Net s...
Breaking Biology Technology:GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7
...ology Holdings, Inc. ("Holdings",or the "Company")...ology"),one of the nation,s largest cancer service...BITDA of $51.3 million, Adjusted EBITDA of $58.0 m...h flow of $74.2 million for the,quarter ended Dece...7, the,Company reported revenue of $3.0 billion, E...
...ansgenomic Inc. (OTC,Bulletin Board: TBIO) announc...ic Inc. Fourth Quarter 2007 Earnings Release ...uary 28, 2008 @ 5:00 p.m. Eastern, Where: ht... Live over the Internet -- Simply log on to t...ss the call via telephone, call 800-895-1085 or 78...
...ORD, England, February 28, Evotec AG (Frankfurt St...s first Phase II study for EVT 302 in smoking,cess... of monoamine oxidase,B (MAO-B)., This double-bli...stigate the influence of EVT 302 on craving and wi...cigarettes in 90 smokers. Smokers will,receive a s...
Other Biology Technology:US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 2US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 3US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 4US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 5US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 6US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 7US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 8US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 9US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 10US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 11US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 12US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 13US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 14US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 15US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 16US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 17US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 18US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 19US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 20US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 21US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 22US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 23US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 24US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 25US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 26Evotec Starts Phase II in Smoking Cessation with EVT 302 2